Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy.

Department of Pediatrics, Subdivision of Endocrinology, Sophia Children's Hospital, 3015 GJ Rotterdam, The Netherlands.
Journal of Clinical Endocrinology &amp Metabolism (Impact Factor: 6.43). 03/2002; 87(2):506-12.
Source: PubMed

ABSTRACT We studied bone mineral density (BMD), bone metabolism, and body composition in 47 children with central precocious puberty (n = 36) or early puberty (n = 11) before, during, and after cessation of GnRH agonist. Bone density and body composition were measured with dual energy x-ray absorptiometry and expressed as SD scores. Bone age and biochemical parameters of bone turnover were assessed. Measurements were performed at baseline, after 6 months, and on a yearly basis thereafter. Mean lumbar spine BMD SD scores for chronological age were significantly higher than zero at baseline and decreased during treatment. Lumbar spine bone mineral apparent density and total body BMD did not differ from normal at baseline and showed no significant changes during treatment. In contrast, BMD SD scores for bone age were significantly lower than zero at baseline and at cessation of therapy. Two years after therapy, bone mineral apparent density and BMD SD scores for bone age and chronological age did not differ from normal. Markers of bone turnover decreased during treatment, mainly in the first 6 months. Patients had increased percentage of fat and lean body mass at baseline. After an initial increase of percentage body fat during treatment, percentage body fat decreased and normalized within 1 yr after cessation of treatment. Our longitudinal analysis suggests that peak bone mass or body composition will not be impaired in patients with precocious or early puberty after GnRH agonist therapy.

0 0
  • [show abstract] [hide abstract]
    ABSTRACT: OBJECTIVE: To compare final height, change in body mass index (BMI), and time from end of treatment until menarche in girls with central precocious puberty treated with the histrelin implant versus depot gonadotropin releasing hormone agonist injections. STUDY DESIGN: Chart review, interview, and final height measurements of 2 groups of girls with central precocious puberty; triptorelin depot (TD) group: 23 girls were treated from age 8.4 ± 0.3 with monthly injections of TD, for 26.7 ± 2.5 months; histrelin implant group: 11 girls were treated from age 8.7 ± 0.3 years for 28.4 ± 3.7 months, of whom 9 initially received monthly TD injections for 1.5-39 months. Final height, BMI (pretreatment vs recent), and time between either implant removal or last injection to menarche were compared. RESULTS: Time between removal of implant or last injection and menarche was 9.3 ± 1.5 (histrelin implant group) versus 16.1 ± 1.7 (TD group) months (P = .02). Predicted height at implant insertion was 156.8 ± 2.6 cm, and final height was 161.1 ± 2.0 cm (not significant [NS]). Predicted height for TD was 155.2 ± 1.9 cm and final height was 157.9 ± 1.7 cm (NS). Change from onset of treatment to final BMI-SDS for histrelin implant was -0.41 ± 0.3, and for TD was -0.03 ± 0.2 (NS). CONCLUSIONS: Menarche occurred sooner after implant removal. There was no difference in final height or BMI outcomes between the 2 treatment modalities.
    The Journal of pediatrics 02/2013; · 4.02 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Introduction: GnRH analogs represent the drug of choice for medical treatment of central precocious puberty (CPP). They provided prompt and reversible suppression of reproductive axis and several reports have shown that adult height is preserved in treated children. Areas covered: This review updates GnRH analog treatment in CPP by a search of the literature published on the topic since 1980. Expert opinion: Monthly GnRH analogs are currently considered the 'gold standard' for the medical treatment of CPP, since a lot of experience is accumulated on their use in children. Differences in long-term outcome (in terms of adult height) are reported and they may be due to differences in selection criteria, treatment monitoring, criteria to stop of therapy, different biological activity of the various drugs and different genetic background of treated patients; altogether, these items remain poorly evaluated. Psychological indications for treatment and long-term psychological outcome of treated children should be better addressed. Comparative trials among the various GnRH analogs are very scarce. New very long-acting GnRH analogs (quarterly or yearly formulations) may improve compliance with therapy, but longer follow-up studies are needed. Medical treatment of CPP should be close to pediatric endocrinologists or tertiary pediatric endocrinology centers with documented experience in this field.
    Expert Opinion on Pharmacotherapy 06/2013; · 2.86 Impact Factor
  • [show abstract] [hide abstract]
    ABSTRACT: Puberty is a period characterized by growth spurt and rapid change in body composition. The effect of GnRH agonist therapy for central precocious puberty on bone mineral density is unclear. We demonstrated changes in bone mineral density in subjects with central precocious puberty, who were treated with GnRH agonist for more than 3 years. The changes in bone mineral density and body compositions were tested with analysis of variance with repeated measures to identify statistical significance over the treatment period. One hundred ninety-five Korean girls with central precocious puberty were treated with GnRH agonist, and among these subjects, 39 patients were treated for more than 3 years. Dual-energy X-ray absorptiometry was performed on the subjects at the initial evaluation and once yearly thereafter while on the treatment. The bone mineral density parameters for chronological age tended to decrease near the mean for the treatment period; however, they increased significantly for bone age excluding bone mineral apparent density. An increment of the BMI was not significant for the chronological age. Three-year treatment with GnRH agonist in central precocious puberty patients did not impair bone maturation. GnRH agonist could be effectively commenced in girls with precocious puberty from an early age.
    Clinical Endocrinology 04/2012; 77(5):743-8. · 3.40 Impact Factor

Full-text (2 Sources)

Available from
Nov 21, 2013